Pneumocystis Jirovecii Pneumonia Prophylaxis

Patient Population and Indications

• Patients with HIV infection and a CD4+ T lymphocyte count <200 cells/μL, CD4+ T lymphocyte percentage <14%, history of oropharyngeal candidiasis, history of AIDS-defining illness, or constitutional symptoms like unexplained fever >100°F for ≥2 weeks should receive prophylaxis, as recommended by the CDC 1, 2, 3
• Any patient who has recovered from a documented episode of PCP should receive prophylaxis, unless immune reconstitution occurs, as recommended by the CDC 3, 4
• Patients on triple immunosuppressive therapy, particularly those on corticosteroids, thiopurine, and either a calcineurin inhibitor or infliximab, should be considered for prophylaxis, as recommended by the European League Against Rheumatism and the European Society for Clinical Microbiology and Infectious Diseases 5, 6
• Patients with multiple myeloma receiving bispecific antibody therapy, and those with other autoimmune inflammatory rheumatic diseases on high-dose glucocorticoids, especially when combined with other immunosuppressants, should be considered for prophylaxis, according to the European League Against Rheumatism 6, 7
• Infants aged 1-12 months with HIV infection or HIV-indeterminate status should receive TMP-SMX 150/750 mg/m²/day in 2 divided doses three times weekly on consecutive days, as recommended by the Centers for Disease Control and Prevention 2
• HIV-infected children aged 1-5 years with CD4+ count <500/μL or CD4+ percentage <15%, and those aged 6-12 years with CD4+ count <200/μL or CD4+ percentage <15%, should receive prophylaxis, as recommended by the Centers for Disease Control and Prevention 2

Dosage and Administration

• The American Gastroenterological Association recommends a first-line option of one double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) three times weekly for PJP prophylaxis, with the Centers for Disease Control and Prevention (CDC) also recommending effective regimens including one double-strength tablet daily, one single-strength tablet daily, and one double-strength tablet three times weekly 1, 2, 5
• For patients with creatinine clearance 15-30 mL/min, the standard dose of TMP-SMX should be halved 8
• For patients with creatinine clearance <15 mL/min, consideration of an alternative agent is recommended 8

Alternative Prophylaxis Agents

• For patients with sulfa allergies or intolerance to TMP-SMX, alternative regimens include:

Monitoring and Adverse Effects

• Complete blood count with differential and platelet count should be performed at initiation and monthly thereafter to monitor for adverse effects of TMP-SMX, including cytopenias and renal toxicity, in patients receiving PCP prophylaxis, as recommended by the CDC and the National Kidney Foundation 4, 9, 10
• Common adverse effects of aerosolized pentamidine include coughing, wheezing, chest pain, and bronchospasm, while common adverse effects of TMP-SMX include rash, pruritus, cytopenias, and transaminase elevations 3
• Up to 70% of patients can tolerate reinstitution of therapy after non-life-threatening adverse reactions, with options including gradual dose increase (desensitization) and reduced dose or frequency 1, 2

Special Considerations

• Evaluate patients for tuberculosis before initiating therapy, and monitor for drug interactions, particularly with methotrexate 3, 10
• Risk factors for PJP include persistent lymphopenia, older age, and pre-existing lung disease, as identified by the European League Against Rheumatism 6
• For life-threatening reactions to TMP-SMX, such as anaphylaxis or Stevens-Johnson syndrome, the medication should be permanently discontinued and an alternative agent should be used, as recommended by the CDC 4